ChronoScale Corporation Common Stock (CHRN) Financials

Financial statement review: The supplied filings identify the company as EKSO BIONICS HOLDINGS, INC., despite the requested ChronoScale Corporation name and CHRN ticker. The analysis below is based on the financial data provided. The available periods are quarterly and do not represent a complete four-year history.

Overall trend: The company continues to generate operating losses and negative operating cash flow. Revenue has weakened from $3.76 million in Q1 2024 to $2.14 million in Q1 2026, while the latest quarter’s net loss widened to $6.89 million. Financing activity, rather than internally generated cash, was responsible for the increase in cash during Q1 2026.

• Gross margin remains relatively resilient. Q1 2026 gross profit was $1.07 million, representing a gross margin of approximately 50.2%. Although below Q3 2025’s roughly 60.3% margin, the company continues to generate positive gross profit despite lower revenue.
• Operating cash burn improved year over year. Net cash used in operating activities was $2.12 million in Q1 2026, compared with $3.47 million in Q1 2024. This improvement was partly supported by positive changes in operating assets and liabilities of $2.67 million.
• Debt balances have declined from earlier periods. Total short- and long-term debt was approximately $3.85 million at March 31, 2026, down from about $5.84 million at March 31, 2025 and $5.36 million at September 30, 2024.
• Liquidity improved during the latest quarter. Cash increased to $3.99 million at March 31, 2026 from $2.72 million at September 30, 2025, and total current assets exceeded current liabilities by approximately $4.96 million.
• Q1 2026 cash growth was primarily financing-driven. Financing activities provided $4.95 million, more than offsetting the $2.12 million operating cash outflow. The reported $5.27 million inflow labeled as a preferred-equity repurchase-related item should be reviewed carefully because its classification is unusual and may not represent recurring funding.
• Capital spending is limited. The company reported no property, plant and equipment purchases in Q1 2026, compared with $126,000 in Q4 2025. Low capital expenditures conserve cash but may also indicate restrained investment in production capacity or infrastructure.
• Revenue has deteriorated. Q1 2026 revenue of $2.14 million declined approximately 36.6% from Q1 2025 and 32% from Q4 2025. Revenue has also generally trended below the $4 million-plus quarterly levels reported in much of 2024 and 2025.
• Operating losses remain substantial. Q1 2026 operating loss was $5.62 million, compared with $4.51 million in Q4 2025 and $3.44 million in Q1 2025. Operating expenses of $6.69 million were more than six times gross profit.
• Net losses are worsening. The Q1 2026 net loss of $6.89 million exceeded the $4.67 million loss in Q4 2025 and the $2.89 million loss in Q1 2025. The loss included $1.12 million of net other expense in the latest quarter.
• Equity dilution and balance-sheet weakness remain key risks. Basic weighted-average shares increased from 1.69 million in Q1 2025 to 3.56 million in Q1 2026. At the same time, retained earnings were negative $269.28 million, total equity fell to $2.09 million, and redeemable noncontrolling interest was $3.65 million. Continued losses and cash burn could require additional financing or equity issuance.

Investor takeaway: The latest statements show some encouraging elements, including lower debt, improved operating cash burn compared with early 2024, and positive gross profit. However, these positives are outweighed by declining revenue, expanding operating losses, persistent dependence on external financing, and a materially weaker equity base. Investors should focus on whether revenue stabilizes, operating expenses decline, and operating cash flow approaches breakeven without relying on additional share issuance or unusual financing transactions.